Key player in Pershing Square's Valeant bet leaving firm
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Valeant (VRX) Derm NRx Up 1% Week-Over-Week, ophth NRx Down 5.1% - RBC
May 13, 2016 12:48 PM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 1.0% WoW, ophth NRx were down 5.1% WoW, and Addyi NRx were down 3.6% WoW.
Miehm commented, "For the week ending May 6th, new derm scripts (NRx) were up 1.0% vs. up 2.2% the prior... More
